RxDoctor Payments Data

Robert Casna, APRN

Psychiatric/Mental Health · Saint Petersburg, FLNPI 1063128106

Payments from drug & device makers

$1,892in general payments, 2019–2025

Across 96 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$576
  • Neurocrine Biosciences, Inc.$184
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$177
  • Otsuka America Pharmaceutical, Inc.$160
  • H2-pharma, LLC$150
  • Alkermes, Inc.$128
  • plus $516 from 7 others

What the payments were for

  • Speaking & faculty fees$1508%
  • Food & beverage$1,74292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,892 in reported general payments places this provider in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$1,506
Medicare patients
15
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$168,062
VraylarCariprazine Hcl33$51,151
Lurasidone Hcl53$4,563
Olanzapine47$4,022
Aripiprazole62$3,708
Olanzapine OdtOlanzapine26$2,535
Divalproex Sodium ErDivalproex Sodium26$2,377
Buspirone Hcl80$1,506
Quetiapine Fumarate72$1,356
Lamotrigine103$1,312
Trazodone Hcl169$1,236
Hydroxyzine Pamoate99$1,146
Divalproex Sodium27$976
Venlafaxine Hcl ErVenlafaxine Hcl31$947
Duloxetine Hcl26$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$184$168,06220 claims
AbbVieVraylar$124$51,15133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →